A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482